Transplant versus no transplant outcome in adolescents and adults with sickle cell disease eligible for allogeneic hematopoietic stem cell transplantation
Cécile Pivert, Loïc Vasseur, Matthieu Jestin, E Flamarion et autres
Hematopoietic stem cell transplantation (HSCT) remains the only curative option for sickle cell disease (SCD), but its use in adolescents and adults is limited by toxicity concerns. We evaluated the risk-benefit profile of HSCT in this population through a comparative analysis of …
fr, us, gp, ch, mq, ca (code pays fourni par la source)